🇺🇸 FDA
Pipeline program

CBD 100 mg/mL Oral Solution

PID-18894

Phase 3 small_molecule active

Quick answer

CBD 100 mg/mL Oral Solution for Treatment Resistant Psychosis is a Phase 3 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COGNITION THERAPEUTICS INC
Indication
Treatment Resistant Psychosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials